NEW YORK (GenomeWeb) – Deutsche Bank has initiated coverage of 17 life science tools and diagnostics companies, noting the sector's high growth rate in recent years as well as its broad exposure to various kinds of customers and geographic locations.

The bank rated Thermo Fisher Scientific, Danaher, Agilent Technologies, Laboratory Corporation of America, Quest Diagnostics, Waters, Hologic, and Bio-Techne at Buy; Illumina, Mettler-Toledo, PerkinElmer, Bio-Rad Laboratories, Bruker, VWR, and Genomic Health at Hold; and Myriad Genetics and Luminex at Sell.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.